Brought to you by 
BMS and Gilead work on HIV combination drug
05 Oct 2006
Executive Summary
Bristol-Myers Squibb and Gilead have formed a joint venture, Bristol-Myers Squibb & Gilead Sciences LLC, to develop and sell in the US a fixed-dosed combination of BMS' Sustiva and Gilead's Truvada, which combines two approved Gilead products Emtriva and Viread.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com